Through human leukocyte antigen molecules, these antigens are presented to (CD4+ or CD8+) T-cells and activate the well-known cascade of tumor-cell recognition, activation, and expansion of effector cells that will induce a tumor-specific immune response. Here, CD8A is linked to neoplasm.